Position of SGLT2i in prediabetes: A systematic review of literature

被引:0
|
作者
Biswas, Kaushik [1 ]
Reddy, Vijaya Bhaskar [2 ]
Seshadri, Krishna [3 ]
Kapoor, Nitin [4 ]
Dharmalingam, Mala [5 ]
Anthuvan, Thamburaj [6 ]
机构
[1] Med Superspecialty Hosp, Dept Endocrinol, Kolkata 700099, W Bengal, India
[2] Vijay Diabet, Dept Diabet & Endocrinol, Thyroid & Endocrine Clin, Pondicherry, India
[3] Chennai Diabet & Endocrinol Clin, Dept Endocrinol, Chennai, India
[4] Christian Med Coll & Hosp, Dept Endocrinol Diabet & Metab, Vellore, Tamil Nadu, India
[5] Bangalore Endocrinol & Diabet Res Ctr, Bangalore, Karnataka, India
[6] Savitribhai Phule Pune Univ, Dept Commerce & Management, Pune, Maharashtra, India
关键词
Cardiovascular complications; diabetes prevention; glycemic control; prediabetes; renal complications; SGLT2; inhibitors; CHRONIC KIDNEY-DISEASE; FOLLOW-UP; DIAGNOSIS; INDIA; EMPAGLIFLOZIN; ASSOCIATION; PREVALENCE; MANAGEMENT; PREDICTORS;
D O I
10.4103/jod.jod_238_24
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. (2002). Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622. Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, et al.; EMBRACE (2018). Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, etal.; ACMG Laboratory Quality Assurance Committee (2015). Standards and guidelines for the interpretation of sequence variants: ajoint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405-424. Sehouli J, Alfaro V, Gonz & aacute;lez-Martin A (2012). Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum- sensitive ovarian cancer: current evidence and future perspectives. Ann Oncol 23:556-562. Shao D, Cheng S, Guo F, Zhu C, Yuan Y, Hu K, et al. (2020). Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals. Cancer Sci 111:647-657. X, L, Kong B, J, R, H, (2017). multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian cancer patients. IntJ Gynecol Cancer 27:1650-1657. Wu Z, Zhang Q, Jin Y, Zhang X, Chen Y, Yang C, et al. (2024). Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area. BMC Cancer 24:411. Yousif HM, Mohammed RA, Missawi HM, Elsawaf ZM, Albasri AM (2019). Histopathological patterns of primary malignant ovarian neoplasms in different age groups in Almadinah Almunawwarah region, KSA. J Taibah Univ Med Sci 14:73-78. Zadabedini Masouleh T, Etchegary H, Hodgkinson K, Wilson BJ, Dawson L (2023). Beyond sterilization: a comprehensive review on the safety and efficacy of opportunistic salpingectomy as a preventative strategy for ovarian cancer. Curr Oncol 30:10152-10165. Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, et al. (2011). Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 121:353-357.
引用
收藏
页码:102 / 114
页数:13
相关论文
共 50 条
  • [21] SGLT2i Dual Therapy with Metformin (Met) for Type 2 Diabetes Mellitus (T2DM)-Systematic Literature Review and Network Meta-analysis (NMA)
    Mcneill, Ann Marie
    Davies, Glenn M.
    Kruger, Eliza
    Reason, Timothy
    Ejzykowicz, Flavia
    Hannachi, Hakima
    Cater, Nilo B.
    Mcleod, Euan
    DIABETES, 2018, 67
  • [22] SAFETY OF SGLT2 INHIBITORS (SGLT2I) IN PEOPLE OVER 75 YEARS
    Marques Vidas, Maria
    Domenech, Ester
    Martin Testillano, Lucia
    Maroto, Alba
    Lopez, Paula
    Portoles, Jose' M.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I104 - I104
  • [23] Early Experience with SGLT2i in Systemic Lupus Erythematosus
    Petri, Michelle
    Goldman, Daniel
    Fava, Andrea
    Magder, Larry
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2941 - 2943
  • [24] SGLT2i: beyond the glucose-lowering effect
    Ni, Lihua
    Yuan, Cheng
    Chen, Guopeng
    Zhang, Changjiang
    Wu, Xiaoyan
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [25] ARNI and SGLT2i: a promising association to be used with caution
    Herbst, Andrea
    Orso, Francesco
    Migliorini, Marta
    Virciglio, Simona
    Tognelli, Silvia
    Camartini, Viola
    Pratesi, Alessandra
    Fattirolli, Francesco
    Marchionni, Niccolo
    Ungar, Andrea
    Baldasseroni, Samuele
    JOURNAL OF GERIATRIC CARDIOLOGY, 2020, 17 (11) : 728 - 732
  • [26] SGLT2i: new perspectives in diabetes and kidney disease
    Ferrannini, Giulia
    Cosentino, Francesco
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (03) : E4 - E4
  • [28] Time to SGLT2i Initiation in Patients With Heart Failure
    Moon, Jungyeon
    Udell, Jacob A.
    Chong, Alice
    Fang, Jiming
    Austin, Peter
    Ko, Dennis T.
    Stukel, Therese
    Atzema, Clare
    Booth, Gillian
    Tu, Karen
    Naimark, David
    Jackevicius, Cynthia
    CIRCULATION, 2023, 148
  • [29] Real world experience of SGLT2i in HFrEF patients
    Saharudin, S.
    Yen, C. H.
    Tan, S. L.
    Kaukiah, N. F.
    Yong, V. S.
    Liew, H. B.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 393
  • [30] Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) Associated Diabetic Ketoacidosis in Oncology Patients: A Case Series and Literature Review
    Alkindi, Fatima
    Boobes, Yousef
    Shalwani, Fatima
    Ansari, Jawaher
    Almazrouei, Raya
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (02)